Mandate

Vinge advises XVIVO in connection with a directed share issue of MSEK 250

November 01, 2021 Capital Markets and Public M&A

Vinge has advised XVIVO Perfusion AB in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 250 to XVIVO.

The subscription price of SEK 335, which corresponded to the closing price on Nasdaq Stockholm, was determined through an accelerated book-building procedure arranged by Carnegie and Bryan, Garnier & Co. The proceeds will be used for the financing of XVIVO’s acquisition of Star Teams Inc. which was published on the same day as the directed share issue.

Vinge’s team primarily consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026